FDA Approves Five Novel Lung Cancer Therapies in 2025, Advancing Precision Medicine and Immunotherapy
Key Insights
The FDA approved five breakthrough lung cancer therapies in 2025, including novel antibody-drug conjugates targeting TROP2 (search) and c-Met (search), and next-generation tyrosine kinase inhibitors for HER2 (search) and ROS1 (search) mutations.
Datopotamab deruxtecan received accelerated approval for EGFR (search)-mutated NSCLC patients who progressed on prior therapies, while telisotuzumab vedotin was approved for c-Met (search) overexpressing tumors.
Small cell lung cancer treatment advanced with the approval of lurbinectedin plus atezolizumab maintenance therapy and full approval of tarlatamab, a DLL3 (search)-targeting bispecific T-cell engager.
The year 2025 marked a transformative period for lung cancer treatment, with the FDA approving five novel therapies that significantly expanded precision medicine options for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. These regulatory decisions emphasized targeted approaches through antibody-drug conjugates (ADCs) and next-generation tyrosine kinase inhibitors (TKIs), while also advancing immunotherapy strategies for aggressive disease subtypes.
Antibody-Drug Conjugates Enter New Biomarker Territories
The FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) on June 23, 2025, for adult patients with locally advanced or metastatic EGFR (search)-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. This TROP2 (search)-targeting ADC addresses a critical unmet need for patients who have exhausted standard TKI and chemotherapy options, offering a targeted alternative to traditional salvage regimens. The approval was based on efficacy data from the TROPION-Lung01 and TROPION-Lung05 trials, establishing TROP2 as a validated therapeutic target in lung cancer.
Earlier in May, the FDA approved telisotuzumab vedotin-tllv (Emrelis), a c-Met (search)-directed ADC, for adult patients with advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression, defined as ≥50% of tumor cells with strong staining. This approval underscores the importance of immunohistochemistry testing for c-Met in the refractory setting and provides a new option for patients whose disease has progressed on or after prior systemic therapy.
Next-Generation TKIs Target Rare Mutations with Precision
Zongertinib (Hernexeos) received accelerated approval on August 8, 2025, for adult patients with unresectable or metastatic non-squamous NSCLC harboring HER2 (search) (ERBB2) tyrosine kinase domain mutations. The Beamion LUNG-1 trial demonstrated an objective response rate of 75% in patients previously treated with platinum-based chemotherapy. Zongertinib's design allows it to spare wild-type EGFR (search), potentially reducing off-target toxicities such as rash and diarrhea that have limited the utility of earlier pan-HER inhibitors.
The FDA also approved taletrectinib (Ibtrozi) on June 11, 2025, for adult patients with locally advanced or metastatic ROS1 (search)-positive NSCLC. This next-generation TKI is capable of crossing the blood-brain barrier, addressing the high incidence of central nervous system metastases in this patient population.
Small Cell Lung Cancer Advances Focus on Survival Extension
Progress in SCLC centered on extending survival and cementing immunotherapy's role. On October 2, 2025, the FDA approved the combination of lurbinectedin (Zepzelca) and atezolizumab (Tecentriq) for maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed following first-line induction therapy with atezolizumab and chemotherapy. This approval was based on the phase 3 IMforte trial, which showed statistically significant improvements in overall survival and progression-free survival compared with atezolizumab maintenance alone.
Tarlatamab-dlle (Imdelltra), a bispecific T-cell engager targeting DLL3 (search), received full FDA approval on November 19, 2025, for patients with extensive-stage SCLC with disease progression on or after platinum-based chemotherapy. The conversion from accelerated to full approval followed results from the phase 3 DeLLphi-304 study, confirming its survival benefit in a heavily pretreated population.
Long-Term Immunotherapy Data Reinforces Treatment Benefits
Six-year data from the CheckMate 9LA trial, published in ESMO Open in 2025, continued to demonstrate overall survival benefits for patients with metastatic NSCLC who received nivolumab and ipilimumab plus chemotherapy. The long-term data showed particularly striking benefits over chemotherapy alone for patients whose tumors were PD-L1 (search) <1%, a historically difficult-to-treat population.
The FDA also approved subcutaneous formulations of both nivolumab and pembrolizumab in 2025, potentially improving patient convenience and treatment administration. Additionally, phase 2 data showed that frontline treatment with izalontamab brengitecan plus osimertinib induced responses in 100% of patients with EGFR (search)-mutated, locally advanced or metastatic NSCLC.
Clinical Impact and Future Directions
These 2025 approvals highlight a clear trajectory toward highly individualized care in lung cancer treatment. The successful integration of TROP2 (search)- and c-Met (search)-directed ADCs, alongside HER2 (search)- and ROS1 (search)-specific TKIs, mandates more comprehensive molecular and protein expression profiling at diagnosis and progression. As these novel agents enter clinical practice, multidisciplinary teams must navigate new toxicity profiles and sequencing strategies to optimize patient outcomes in an increasingly complex treatment landscape.